Download full announcement Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients NEW YORK, August 3, 2020 – Mount Sinai Health System... read more →
Download full announcement For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2020, the Company's issued and fully paid... read more →
Download full announcement Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive... read more →
Download full announcement Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive... read more →
Download full announcement Renalytix AI plc (LSE: RENX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient... read more →
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare... read more →
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare... read more →
Download full announcement NEW YORK, 8 July, 2020 – Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive... read more →
Download full announcement Expands access and coverage of KidneyIntelX™ into key regions for commercial growth Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical... read more →
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare... read more →